[ET Net News Agency, 29 April 2022] Nomura lowered its target price for Innovent Bio
(01801) to HK$43.75 from HK$49.41 and maintained its "buy" rating.
The research house said it cuts FY22/23 revenue forecasts by 6%/8%, to reflect the
fierce competition in PD-1 inhibitors and current COVID-19 impact. (RC)